Vor Biopharma Net Worth
Vor Biopharma Net Worth Breakdown | VOR |
Vor Biopharma Net Worth Analysis
Vor Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vor Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vor Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vor Biopharma's net worth analysis. One common approach is to calculate Vor Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vor Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vor Biopharma's net worth. This approach calculates the present value of Vor Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vor Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vor Biopharma's net worth. This involves comparing Vor Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vor Biopharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Vor Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vor Biopharma's net worth research are outlined below:
| Vor Biopharma had very high historical volatility over the last 90 days | |
| Vor Biopharma has some characteristics of a very speculative penny stock | |
| Vor Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (117.86 M) with profit before taxes, overhead, and interest of 0. | |
| Vor Biopharma has about 151.09 M in cash with (100.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vor Biopharma has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Vor Biopharma Inc. Receives 11.36 Consensus Price Target from Brokerages - MarketBeat |
Vor Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vor Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vor Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Vor Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vor Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vor Biopharma backward and forwards among themselves. Vor Biopharma's institutional investor refers to the entity that pools money to purchase Vor Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 422.1 K | Ensign Peak Advisors Inc | 2024-09-30 | 329.4 K | Millennium Management Llc | 2024-09-30 | 303.8 K | Jane Street Group Llc | 2024-06-30 | 222.5 K | Exchange Traded Concepts, Llc | 2024-09-30 | 165.8 K | Two Sigma Investments Llc | 2024-09-30 | 137.1 K | Bridgeway Capital Management, Llc | 2024-09-30 | 135.9 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 116.6 K | State Street Corp | 2024-09-30 | 115.9 K | Ra Capital Management, Llc | 2024-09-30 | 22.7 M | Fmr Inc | 2024-09-30 | 7.1 M |
Follow Vor Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 59.56 M.Market Cap |
|
Project Vor Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (0.78) | (0.82) |
When accessing Vor Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Vor Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vor Biopharma's profitability and make more informed investment decisions.
Evaluate Vor Biopharma's management efficiency
Vor Biopharma has Return on Asset of (0.3974) % which means that on every $100 spent on assets, it lost $0.3974. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.7807) %, meaning that it generated no profit with money invested by stockholders. Vor Biopharma's management efficiency ratios could be used to measure how well Vor Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/23/2024, Return On Tangible Assets is likely to drop to -0.62. In addition to that, Return On Capital Employed is likely to drop to -0.72. As of 12/23/2024, Net Tangible Assets is likely to grow to about 302.6 M, while Total Assets are likely to drop slightly above 151.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.24 | 1.96 | |
| Tangible Book Value Per Share | 2.24 | 1.96 | |
| Enterprise Value Over EBITDA | (1.36) | (1.43) | |
| Price Book Value Ratio | 1.00 | 0.95 | |
| Enterprise Value Multiple | (1.36) | (1.43) | |
| Price Fair Value | 1.00 | 0.95 | |
| Enterprise Value | 178.8 M | 169.9 M |
The management team at Vor Biopharma has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Return On Equity (0.78) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vor Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vor Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vor Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vor Biopharma time-series forecasting models is one of many Vor Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vor Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Vor Biopharma Earnings per Share Projection vs Actual
Vor Biopharma Corporate Management
| PharmD D | Chief Officer | Profile | |
| Samir MS | Senior Management | Profile | |
| Han MD | Chief Officer | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Eyal MD | Chief Officer | Profile | |
| Tania Philipp | Chief Officer | Profile | |
| MBA MD | CEO Pres | Profile |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.